

Resource Summary Report

Generated by [dkNET](#) on Aug 31, 2026

OCI-Ly3

RRID:CVCL_8800

Type: Cell Line

Proper Citation

RRID:CVCL_8800

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_8800

Proper Citation: RRID:CVCL_8800

Description: Cell line OCI-Ly3 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Diffuse large B-cell lymphoma activated B-cell type

Defining Citation: [PMID:3567358](#), [PMID:8574164](#), [PMID:10676951](#), [PMID:11807979](#), [PMID:15122589](#), [PMID:18323416](#), [PMID:19278952](#), [PMID:20054396](#), [PMID:20628145](#), [PMID:20889926](#), [PMID:21179087](#), [PMID:22460905](#), [PMID:23257783](#), [PMID:23292937](#), [PMID:23321251](#), [PMID:23699601](#), [PMID:25485619](#), [PMID:26589293](#), [PMID:28196595](#), [PMID:29416618](#), [PMID:29666304](#), [PMID:30285677](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31978347](#)

Comments: Caution: A cell line, now termed GNE-587170 (Cellosaurus=CVCL_AT69), was mistakenly distributed by OCI to a number of groups under the designation OCI-Ly-3, the origin of that cell line is now known., Population: Caucasian., From: Ontario Cancer Institute (OCI); Toronto; Canada., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OCI-Ly3

Synonyms: OCI-LY3, OCI-Iy3, OCI-LY-3, Oci-Ly-3, OCI-Ly 3, OCILY-3, OCI-Ly03, OCI Ly3, OCILY3, Ly3, LY3

Cross References: EFO:EFO_0006710, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioGRID_ORCS_Cell_line:745, BioSample:SAMN10988130, cancercellines:CVCL_8800, Cell_Model_Passport:SIDM01778, ChEMBL-Cells:ChEMBL4523534, ChEMBL-Targets:ChEMBL4523565, Cosmic:1290019, Cosmic:1329094, Cosmic:1486584, Cosmic:1487544, Cosmic:1517647, Cosmic:1541901, Cosmic:1548654, Cosmic:1550337, Cosmic:1945198, Cosmic:2276329, Cosmic:2437309, DepMap:ACH-000158, DSMZ:ACC-761, DSMZCellDive:ACC-761, EGA:EGAS00001000610, ENCODE:ENCBS018GXW, ENCODE:ENCBS757GPD, GEO:GSM1963, GEO:GSM2023, GEO:GSM380133, GEO:GSM552451, GEO:GSM887472, GEO:GSM888552, GEO:GSM1035342, GEO:GSM1059799, GEO:GSM1374787, GEO:GSM1890025, GEO:GSM1890026, GEO:GSM1890027, GEO:GSM1890028, GEO:GSM3150251, IARC_TP53:26922, LiGeA:CCLE_060, Lonza:945, PharmacDB:OCILY3_1189_2019, PRIDE:PXD012087, Progenetix:CVCL_8800, PubChem_Cell_line:CVCL_8800, Wikidata:Q54931773

ID: CVCL_8800

Record Creation Time: 20220427T221355+0000

Record Last Update: 20260829T235504+0000

Ratings and Alerts

No rating or validation information has been found for OCI-Ly3.

No alerts have been found for OCI-Ly3.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 24 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zhao J, et al. (2026) Construction and experimental verification of a prognostic model based on tumor-infiltrating lymphocytes related genes (TILRGs) in diffuse large B-cell lymphoma. SLAS technology, 39, 100425.

Xu ZZ, et al. (2026) A nanosensor platform for cell gene transfection and single-cell nanovibration dynamic monitoring. Talanta, 303, 129486.

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell, 44(7), 1437.

L????nd F, et al. (2025) DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. Blood

cancer discovery, 6(6), 580.

Chen Z, et al. (2025) YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. *Cell*, 188(2), 331.

Qiao Q, et al. (2025) Metabolism-related ALDH1B1 acts as potential predictor and therapeutic target for primary gastrointestinal diffuse large B-cell lymphoma. *Apoptosis : an international journal on programmed cell death*, 30(5-6), 1482.

Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. *Cancer cell*, 42(5), 833.

Eiken AP, et al. (2024) Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects. *Cancer research communications*, 4(5), 1328.

Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. *Blood cancer discovery*, 5(6), 417.

Eken JA, et al. (2024) Antigen-independent, autonomous B cell receptor signaling drives activated B cell DLBCL. *The Journal of experimental medicine*, 221(5).

He MY, et al. (2024) GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma. *Leukemia*, 38(10), 2210.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. *Cancer research communications*, 3(4), 576.

Venturutti L, et al. (2023) An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas. *Cancer discovery*, 13(1), 216.

Scheich S, et al. (2023) Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas. *Cancer discovery*, 13(8), 1862.

Yang X, et al. (2023) Potential role of the P2X7 receptor in the proliferation of human diffused large B-cell lymphoma. *Purinergic signalling*.

Roider T, et al. (2021) The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial. *International journal of cancer*, 148(1), 150.

Dersh D, et al. (2021) Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. *Immunity*, 54(1), 116.

Sadras T, et al. (2021) Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer. *Molecular cell*, 81(10), 2094.

Portelinha A, et al. (2021) ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. *Cell reports. Medicine*, 2(7), 100350.

Qiu Z, et al. (2020) MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome. *Cell chemical biology*, 27(5), 538.